Drug Type CAR-NK |
Synonyms Anti-CD19-CAR viveNK™ cells(Glycostem) |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Preclinical | Netherlands | 01 Nov 2024 | |
B-Cell Leukemia | Preclinical | Netherlands | 06 Nov 2022 |